<DOC>
	<DOC>NCT00441441</DOC>
	<brief_summary>This study is to assess the safety of an investigational drug in children 4 to 11 years of age who have asthma. The subjects will attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests performed.</brief_summary>
	<brief_title>A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Must have asthma. Must be currently taking an inhaled corticosteroid. Must be able to attend 7 clinic visits, of which up to 3 will be in the morning, and have lung function tests that are at least 60% of normal (AM FEV1 or PEF). Have a historical or current FEV1 or PEF reversibility of &gt;=12%. Exclusion criteria: Has ever had lifethreatening asthma (for example respiratory arrest, mechanical ventilation). Has a current ear or respiratory tract infection. Has ever had any other major illnesses (such as cystic fibrosis, heart problems, tuberculosis).</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>fluticasone propionate</keyword>
	<keyword>children</keyword>
	<keyword>fluticasone propionate/salmeterol</keyword>
</DOC>